Microbial immunology is a branch of immunology that focuses on understanding the interactions between the immune system and microorganisms, including bacteria, viruses, fungi, and parasites. This field explores how the immune system recognizes, responds to, and defends against microbial invaders. Key areas of microbial immunology research include the identification of microbial antigens, the activation of immune cells such as macrophages and lymphocytes, and the development of immune memory against specific pathogens. The study of host-pathogen interactions provides insights into the mechanisms of infection, immune evasion strategies employed by microbes, and the development of novel therapeutic interventions. Microbial immunology plays a vital role in vaccine development, as vaccines aim to harness the immune system's ability to recognize and eliminate pathogens. Understanding microbial immunology is crucial for advancing our knowledge of infectious diseases, improving diagnostics, and developing effective strategies for infection prevention and treatment. Ongoing research in this field contributes to the development of innovative immunotherapies and antiviral drugs, ultimately enhancing our ability to combat microbial infections.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States